Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Brain Res. 2010 Nov 18;1361:93-101. doi: 10.1016/j.brainres.2010.09.025. Epub 2010 Sep 21.
Our previous studies have found that intracerebral pretreatment with a low dose of thrombin (thrombin preconditioning, TPC) reduces infarct volume and attenuates brain edema after focal cerebral ischemia. In this study, we examined whether TPC protects against the neuronal death induced by oxygen glucose deprivation (OGD), and whether the protection is through thrombin receptors and the p44/42 mitogen activated protein kinases (MAPK)/ribosomal protein S6 kinases (p70 S6K) pathway. Expression of protease-activated receptors (PARs) mRNA was detected in cultured primary rat neurons and thrombin upregulated PAR-1 and PAR-4 mRNA expression. TPC reduced OGD-induced neuronal death (e.g. dead cells: 52.5 ± 5.4% vs. 72.3 ± 7.2% in the control group, n=6, p<0.01). Agonists of PAR-1 and PAR-4 mimicked the effects of thrombin and reduced OGD-induced neuronal death. Pretreatment with thrombin or PAR agonists induced the upregulation of activated p44/42 MAPK and p70S6K (Thr 421/Ser 424). PD98059, an inhibitor of p44/42 MAPK kinase, blocked thrombin-induced upregulation of activated p44/42 MAPK and p70S6K. It also reduced TPC-induced neuronal protection (e.g. dead cells: 68.2 ± 5.2% vs. 56.9 ± 4.6% in vehicle+TPC group, n=6, p<0.05). These results suggest that TPC-induced ischemic tolerance is through activation of thrombin receptors and the p44/42 MAPK/p70S6K pathway.
我们之前的研究发现,脑内给予小剂量凝血酶预处理(凝血酶预处理,TPC)可减少局灶性脑缺血后的梗死体积和脑水肿。在这项研究中,我们研究了 TPC 是否能防止氧葡萄糖剥夺(OGD)引起的神经元死亡,以及这种保护作用是否通过凝血酶受体和丝裂原活化蛋白激酶(MAPK)/核糖体蛋白 S6 激酶(p70S6K)途径实现。在原代培养的大鼠神经元中检测到蛋白酶激活受体(PARs)mRNA 的表达,凝血酶上调 PAR-1 和 PAR-4 mRNA 的表达。TPC 减少 OGD 诱导的神经元死亡(例如,死亡细胞:对照组为 72.3±7.2%,n=6,p<0.01)。PAR-1 和 PAR-4 的激动剂模拟了凝血酶的作用,减少了 OGD 诱导的神经元死亡。TPC 或 PAR 激动剂预处理诱导激活的 p44/42MAPK 和 p70S6K(Thr421/Ser424)的上调。p44/42MAPK 激酶抑制剂 PD98059 阻断了凝血酶诱导的激活的 p44/42MAPK 和 p70S6K 的上调。它还减少了 TPC 诱导的神经元保护(例如,死亡细胞:对照组为 68.2±5.2%,n=6,p<0.05)。这些结果表明,TPC 诱导的缺血耐受是通过激活凝血酶受体和 p44/42MAPK/p70S6K 途径实现的。